Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ALK mutation
i
Other names:
NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
238
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
ALK positive (73)
ALK negative (4)
EGFR negative + ALK negative (4)
EGFR expression + ALK positive (3)
ALK expression + PDGFRA expression (1)
ALK expression + PDGFRB expression (1)
ALK overexpression (1)
ALK positive + ROS1 positive (1)
ALK positive + YAP1 overexpression (1)
ALK positive + YES1 overexpression (1)
KRT7 positive + NKX2-1 positive + ALK overexpression (1)
ALK positive (73)
ALK negative (4)
EGFR negative + ALK negative (4)
EGFR expression + ALK positive (3)
ALK expression + PDGFRA expression (1)
ALK expression + PDGFRB expression (1)
ALK overexpression (1)
ALK positive + ROS1 positive (1)
ALK positive + YAP1 overexpression (1)
ALK positive + YES1 overexpression (1)
KRT7 positive + NKX2-1 positive + ALK overexpression (1)
›
Associations
(20)
News
Trials
Search handles
@ADesaiMD
@CharuAggarwalMD
@Dr_R_Kurzrock
@JessicaJLinMD
@Joshua_Reuss
@MLPOncoData
@PatrickCMa1
@RManochakian
@StephenVLiu
@SyedMAhmedMDPhD
@aakonc
@esinghimd
@n8pennell
@oncoOuLungCA
@realbowtiedoc
Search handles
@ADesaiMD
@CharuAggarwalMD
@Dr_R_Kurzrock
@JessicaJLinMD
@Joshua_Reuss
@MLPOncoData
@PatrickCMa1
@RManochakian
@StephenVLiu
@SyedMAhmedMDPhD
@aakonc
@esinghimd
@n8pennell
@oncoOuLungCA
@realbowtiedoc
Filter by
Latest
10ms
🔥🚨@OncoAlert Just out @JTOonline by our team @MayoCancerCare: #CaseReport on a sequential #SmallCell transformation & #ALK I1171T mutation as resistance mechanisms in a pt with #ALK-EML4 #NSCLC treated with combination of #Temozolomide & #Lorlatinib 👇🏼 https://t.co/GkixRkDWr5 (@RManochakian)
10 months ago
ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)
|
ALK mutation • ALK I1171T • ALK I1171 • EML4-ALK I1171T
|
temozolomide • Lorbrena (lorlatinib)
10ms
ALK Mutation is present in 2.81% of @AACR GENIE cases, with lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, breast invasive ductal carcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence. https://t.co/xqPTiPcovZ @ALKPositiveinc… https://t.co/KcF0yqWyPP (@4baseCare)
10 months ago
Clinical
|
ALK (Anaplastic lymphoma kinase)
|
ALK mutation
11ms
Quite an interesting work by @alexdrilon group. SHP2 does not work by itself, but it seems to restore efficacy of TKIs in heavily pretreated patients, including ALK+ NSCLC and BRAF V600E mutant CRC. @GBOT_Alerta #ASCO23 #LCSM (@MarceloCorassa)
11 months ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600 • ALK mutation
11ms
#ASCO23 Abs9003 #LCSM "Final OS analysis of CHOICE-01: Toripalimab + chemotherapy in 1st line advanced NSCLC." ➡️465 pts without EGFR/ALK mutations, toripalimab arm showed significant OS improvement over placebo: HR=0.73 (95% CI: 0.57-0.93), median OS 23.8 vs 17.0 months 🎯.… https://t.co/ZfrJA0cZAm (@ADesaiMD)
11 months ago
Clinical • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
ALK mutation
|
Loqtorzi (toripalimab-tpzi)
1year
Mechanisms of resistance to ALK TKIs are: ALK alterations (mutation and amplification), bypass signal pathways (EGFR/HER3, KIT proto-oncogene receptor tyrosine kinase, KRAS, ILGF-R, M-E-T-HGF, MAPK, and others (E-M-T, P-gp, TP53, transformation to SCLC) https://t.co/oXjoSjwflx (@MLPOncoData)
1 year ago
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
|
ALK mutation • ERBB3 mutation
1year
Dr. @jpmd901 with a great comprehensive discussion of treatment strategies for ALK & ROS1-mutated NSCLC at #TexasLung23. Excellent to see the breadth of therapies in and emerging in this space. @TLCconference (@Joshua_Reuss)
1 year ago
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ALK mutation • ROS1 mutation
1year
EGFR/ALK/ROS1 mutated/rearranged NSCLC? The suspense is killing us all… (@DrBenKong)
1 year ago
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK rearrangement • ALK mutation • ROS1 mutation
1year
Do recall, in PACIFIC, pts w/ EGFR/ALK mutations were NOT excluded from enrollment -43/713 (6%) pts had EGFR-mutant disease -PFS in this group HR 0.76 (95% CI 0.35-1.64) #lcsm #TTLC23 (@esinghimd)
1 year ago
Clinical
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK mutation
1year
What happens with ALK NSCLC? On target mutations are monitored by biopsy, but with the 3rd generation, complex ALK mutations present. What to do then? Clin trials for 4th gen ALK TKIs for these complex mutations. @JessicaJLinMD #winterlung (@KellyMercierPh1)
1 year ago
Biopsy
|
ALK (Anaplastic lymphoma kinase)
|
ALK mutation
over1year
Thx. I’ll try to read it slowly. I ask because I had thought that ALK was a driver, or causative, mutation in lung cancer. Is it just an actionable mutation to attack that was not the cause of the cancer? (@DrdelaCruzMunoz)
over 1 year ago
ALK (Anaplastic lymphoma kinase)
|
ALK mutation
almost2years
Why is there not more excitement for batiraxcept after impressive ASCO data... I am over the moon excited... would love my brother to get access to treat Metastatic NSCLC with ALK mutation, bc AXL is key to its spread. https://t.co/oEdYfRItvY (@dexion10)
almost 2 years ago
ALK (Anaplastic lymphoma kinase) • AXL (AXL Receptor Tyrosine Kinase)
|
ALK mutation
|
batiraxcept (AVB-500)
almost2years
Analysis of #lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer” by @JessicaJLinMD #AaronNHata #SatoshiYoda #AyaShiba, et al. #alk #positive #research #NSCLC @NatureCancer (@ALK_Research)
almost 2 years ago
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK mutation
|
Lorbrena (lorlatinib)
almost2years
But also recognize that in many ALK+ lung cancers resistant to lorlatinib, analysis does not identify on-target resistance with ALK mutations. Effective strategies to target/overcome off-target resistance remains a major challenge and an urgent need. (@JessicaJLinMD)
almost 2 years ago
ALK (Anaplastic lymphoma kinase)
|
ALK mutation
|
Lorbrena (lorlatinib)
almost2years
@DrHendifar @PancPathologist have had success w/ #ALK fusion in metastatic #PDAC following #FOLFIRINOX responsive to #alectinib then acquired alectinib-resistant ALK mutations G1202R and V1180L on G360, then w/benefit to 3rd-gen ALK inh #lorlatinib https://t.co/JnI2dntOfv #pancsm ()
almost 2 years ago
ALK (Anaplastic lymphoma kinase)
|
ALK fusion • ALK mutation • ALK G1202R • ALK V1180L
|
Guardant360® CDx
|
5-fluorouracil • Alecensa (alectinib) • Lorbrena (lorlatinib) • leucovorin calcium
almost2years
Shout out to my fellow #GIonc crew. Have a young Burmese patient with EMLA-ALK fusion mutation via NGS in metastatic #crcsm, progressing on 2nd line FOLFOXIRI. Very scant data in alectinib in this setting. Anyone with clinical experience? @pashtoonkasi @marklewismd @doctorC369 (@realbowtiedoc)
almost 2 years ago
Clinical • Next-generation sequencing
|
ALK (Anaplastic lymphoma kinase)
|
ALK fusion • ALK mutation
|
5-fluorouracil • Alecensa (alectinib) • oxaliplatin • leucovorin calcium
2years
ALK as another tumor agnostic marker? MyPath pilot for alectinib. Disease control rate = 60% in ALK rearranged including PRs in colon and pancreatic and uterine leiomyosarcoma. No responses in ALK mutated or amplified (@Dr_R_Kurzrock)
2 years ago
Pan tumor
|
ALK (Anaplastic lymphoma kinase)
|
ALK rearrangement • ALK mutation
|
Alecensa (alectinib)
2years
Acquired resistance to #ROS1 TKIs explained by Dr. @christine_lovly. Have to consider on-target and off-target mechanisms and just as in ALK, compound mutations present a therapeutic challenge. Emerging drugs showing promise here. #LCSM #TTLC22 (@StephenVLiu)
2 years ago
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ALK mutation
2years
Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC https://t.co/Wvv0xjHr0B #ALK #lungcancer #PrecisionMedicine @MNagasaka @ViolaWZhu and Dr. Shannon S. Zhang. (@oncoOuLungCA)
2 years ago
ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • EML4 (EMAP Like 4)
|
TP53 mutation • ALK positive • ALK fusion • ALK mutation
over2years
There are a multitude of onc drivers in ALK mutations in #lungcancer says @AnastasiosDimo1 @OncLiveSOSS #ipc with chair @KArnaoutakis @uamshealth @MayoCancerCare how to chose an inhibitor in front line and then how to treat upon progression (@donnashort)
over 2 years ago
ALK (Anaplastic lymphoma kinase)
|
ALK mutation
over2years
Is there anyone pioneering treatment for clients diagnosed with ALK mutations in non-metastatic NSCLC 3a-b? (@KyleMcnease)
over 2 years ago
ALK (Anaplastic lymphoma kinase)
|
ALK mutation
over2years
Great work! As a bioethicist looking at things from the outside, can anyone point me towards the rationale for using SOC in non-metastatic NSCLC with ALK mutations until treatment failure before utilizing therapies strictly aimed at stage 4 metastatic NSCLC with ALK mutations? (@KyleMcnease)
over 2 years ago
ALK (Anaplastic lymphoma kinase)
|
ALK mutation
over2years
Another reminder in #JCOPO @ASCO_pubs that when pathogenic gene fusions are found, they're often viable targets (as this #ALK fusion in breast cancer). Mutations are much more variable so important to note the details when you get your reports. https://t.co/EzCttpWMsP (@StephenVLiu)
over 2 years ago
ALK (Anaplastic lymphoma kinase)
|
ALK fusion • ALK mutation
almost3years
■memo Risk of thromboembolism in pts w/ ALK- and EGFR-mutant lung cancer: https://t.co/Xl2tG6Lk1X @JTHjournal @aakonc #CardioOnc Pts w/ ALK-mutant advanced LK have the highest rate of TE. These findings should be taken into consideration in decision-making in pts management. (@OncoCard_Ganken)
almost 3 years ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • ALK mutation • EGFR mutation + ALK mutation
over3years
Risk of thromboembolism in patients with ALK‐ and EGFR‐mutant lung cancer: A cohort study https://t.co/k5P4GvAWhJ @ALKLungCancer patients had 43% risk of VTE! #LCSM @EGFRResisters @aakonc @VamsiVelcheti (@n8pennell)
over 3 years ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • ALK mutation
over3years
Proteasome inhibition may overcome ALK-TKI resistance in ALK-Rearranged/TP53-Mutant #NSCLC @CCR_AACR #LCSM @ALKLungCancer @alk_fusion https://t.co/5sd0lD4f4Q (@CharuAggarwalMD)
over 3 years ago
ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53)
|
TP53 mutation • ALK rearrangement • ALK fusion • ALK mutation
over3years
New article: #Thrombosis common in non‐small cell lung #cancer pts & ➡️worse outcomes. Roopkumar @MayoClinic et al @aakonc @ClevelandClinic analyse thrombotic events for ALK & EGFR mutant 🧬 subtypes of NSCLC lung cancer pts; ALK mutation 📈 thrombosis https://t.co/udJkqpy0jZ (@JTHjournal)
over 3 years ago
Clinical
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK mutation
over3years
Our new data re #VTE rates assoc w EGFR and ALK mutations in lung cancer w/ Joanna Roopkumar @poudelmd @GervasoLorenzo @n8pennell @VamsiVelcheti @Keith_R_M @JTHjournal (@aakonc)
over 3 years ago
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK mutation
over3years
#OncoAlert Report in @JTOonline on #ALK NSCLC with 21 patients that underwent biopsy after ALK TKI therapy. Noted several ALK solvent front mutations, SCLC and sarcomatoid transformation. Included several novel ALK mutations as well. #LCSM @IASLC https://t.co/Prt6Eb3QpU (@StephenVLiu)
over 3 years ago
Clinical
|
ALK (Anaplastic lymphoma kinase)
|
ALK mutation
over3years
Enjoyed the impt NACLC20 Oral Abstract on Real-world PFS in oncogene driver-mutated NSCLC treated w single-agent IO. KRAS mutations stand out as different from EGFR/ALK, but more similar to BRAF mutants. Limitation: Line of Rx not known. (@PatrickCMa1)
over 3 years ago
Clinical • Real-World Evidence
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase)
|
KRAS mutation • BRAF mutation • ALK mutation • EGFR mutation + KRAS mutation
over3years
#OncoAlert Report @JTOonline @IASLC on phase II #ATOMIC study of brigatinib in #ALK NSCLC after next-gen ALK TKI therapy. RR 40%, DOR 5.3m, mPFS 7m. Responses seen with ALK resistance mutations (G1202R, I1171T, L1196M). @rdoebele @HornLeora #LCSM https://t.co/aoWJ1Gu0NP (@StephenVLiu)
over 3 years ago
ALK (Anaplastic lymphoma kinase)
|
ALK mutation • ALK G1202R • ALK I1171T • ALK I1171 • ALK L1196M • ALK L1196M + ALK G1202R
|
Alunbrig (brigatinib)
over3years
Liquid biopsies! The reason my husband is still farming 700 acres by himself, 5 years after his stage 4 lung cancer diagnosis. Liquid biopsy found the ALK mutation at diagnosis and the G1202R mutation at progression & both led to a decisive treatment plan. Thank you #harvest2020 (@RhondaMeckstro1)
over 3 years ago
ALK (Anaplastic lymphoma kinase)
|
ALK mutation • ALK G1202R
almost4years
#ASCO20 Response to brigatinib (post-alectinib) noted in the presence of various #ALK resistance mutations including G1202R (1/3), L1196M (3/3), I1171N (1/2), I1171S (1/1). Well tolerated. Most common G3 tox were lipase (no pancreatitis), CK (no myalgias), HTN. #OncoAlert #LCSM (@StephenVLiu)
almost 4 years ago
ALK (Anaplastic lymphoma kinase)
|
ALK mutation • ALK G1202R • ALK I1171N • ALK I1171 • ALK L1196M • ALK I1171S • ALK L1196M + ALK G1202R
|
Alecensa (alectinib) • Alunbrig (brigatinib)
4years
@Jbauml @StephenVLiu . In looking at #COVID19 in #lcsm @ #AACR20, was any data presented on egfr/alk/ros mutation? Is it truly lung cancer that was the risk factor or was lung cancer a surrogate for pre-existing lung disease? (@SyedMAhmedMDPhD)
4 years ago
Clinical
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK mutation
4years
"Great collab @GustaveRoussy @CLCCLeonBerard 💉 ctDNA is clinically relevant for our #ALK #ROS1 #NSCLC patients. One example: at 2ndG-TKI failure, we detected 29% ALK resist. mutations. Will we guide TKI therapy by ctDNA? 🙂@AurelieSwalduz @BenjaminBesseMD & P. Saintigny @Inivata" (@LauraMezquitaMD)
4 years ago
Clinical
|
ALK (Anaplastic lymphoma kinase)
|
ALK mutation
4years
Great collab @GustaveRoussy @CLCCLeonBerard 💉 ctDNA is clinically relevant for our #ALK #ROS1 #NSCLC patients. One example: at 2ndG-TKI failure, we detected 29% ALK resist. mutations. Will we guide TKI therapy by ctDNA? 🙂@AurelieSwalduz @BenjaminBesseMD & P. Saintigny @Inivata (@LauraMezquitaMD)
4 years ago
Clinical
|
ALK (Anaplastic lymphoma kinase)
|
ALK mutation
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login